Get the Stockscreener App
222.82
0.66%
-1.49
Pre-market:
223.15
0.33
+0.15%
Overview
News
Price History
Option Chain
Financials
Why ABBV Down?
Discussions
Forecast
Dividend History
Abbvie Inc stock is traded at $222.82, with a volume of 5.02M.
It is down -0.66% in the last 24 hours and down -4.72% over the past month.
AbbVie is a pharmaceutical firm with a strong exposure to immunology (with Humira, Skyrizi, and Rinvoq) and oncology (with Imbruvica and Venclexta). The company was spun off from Abbott in early 2013. The 2020 acquisition of Allergan added several new products and drugs in aesthetics, including Botox. The 2024 acquisitions of Cerevel (neuroscience) and ImmunoGen (oncology) help supplement AbbVie's portfolio.
See More
Previous Close:
$224.31
Open:
$224
24h Volume:
5.02M
Relative Volume:
0.85
Market Cap:
$393.81B
Revenue:
$59.64B
Net Income/Loss:
$2.36B
P/E Ratio:
168.13
EPS:
1.3253
Net Cash Flow:
$19.68B
1W Performance:
-0.52%
1M Performance:
-4.72%
6M Performance:
+20.13%
1Y Performance:
+28.78%
1-Day Range:
$222.79
$226.26
1-Week Range:
$221.10
$228.30
52-Week Range:
$164.39
$244.81
Abbvie Inc Stock (ABBV) Company Profile
Name
Abbvie Inc
Sector
Industry
Phone
(847) 932-7900
Address
1 NORTH WAUKEGAN ROAD, NORTH CHICAGO, IL
Compare ABBV with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ABBV
Abbvie Inc
|
222.82 | 396.44B | 59.64B | 2.36B | 19.68B | 1.3253 |
|
LLY
Lilly Eli Co
|
1,056.88 | 932.42B | 59.42B | 18.41B | 6.44B | 20.22 |
|
JNJ
Johnson Johnson
|
208.31 | 506.75B | 92.15B | 25.12B | 20.46B | 10.36 |
|
NVS
Novartis Ag Adr
|
135.27 | 259.09B | 54.45B | 14.42B | 17.15B | 7.333 |
|
MRK
Merck Co Inc
|
100.69 | 246.17B | 63.90B | 19.05B | 13.05B | 7.5596 |
Abbvie Inc Stock (ABBV) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-10-25 | Upgrade | HSBC Securities | Hold → Buy |
| Nov-13-25 | Initiated | Scotiabank | Sector Outperform |
| Nov-04-25 | Downgrade | DZ Bank | Buy → Hold |
| Oct-14-25 | Downgrade | Erste Group | Buy → Hold |
| Oct-01-25 | Downgrade | HSBC Securities | Buy → Hold |
| Sep-17-25 | Upgrade | Berenberg | Hold → Buy |
| Aug-12-25 | Resumed | Piper Sandler | Overweight |
| Aug-07-25 | Upgrade | Daiwa Securities | Neutral → Outperform |
| May-14-25 | Downgrade | Citigroup | Buy → Neutral |
| Apr-22-25 | Initiated | Cantor Fitzgerald | Overweight |
| Dec-10-24 | Resumed | BofA Securities | Neutral |
| Dec-05-24 | Downgrade | Daiwa Securities | Outperform → Neutral |
| Nov-22-24 | Upgrade | Leerink Partners | Market Perform → Outperform |
| Nov-15-24 | Initiated | Wolfe Research | Outperform |
| Nov-04-24 | Upgrade | Argus | Hold → Buy |
| Oct-17-24 | Initiated | Bernstein | Mkt Perform |
| Jun-05-24 | Upgrade | HSBC Securities | Hold → Buy |
| May-17-24 | Initiated | Cantor Fitzgerald | Overweight |
| Jan-29-24 | Upgrade | William Blair | Mkt Perform → Outperform |
| Dec-18-23 | Downgrade | HSBC Securities | Buy → Hold |
| Dec-11-23 | Upgrade | Goldman | Neutral → Buy |
| Nov-09-23 | Initiated | Deutsche Bank | Hold |
| Oct-30-23 | Upgrade | Barclays | Equal Weight → Overweight |
| Oct-20-23 | Resumed | UBS | Neutral |
| Sep-29-23 | Initiated | Raymond James | Outperform |
| Jul-25-23 | Initiated | William Blair | Mkt Perform |
| Jul-14-23 | Initiated | HSBC Securities | Buy |
| Apr-05-23 | Downgrade | Argus | Buy → Hold |
| Mar-01-23 | Initiated | Guggenheim | Buy |
| Feb-22-23 | Downgrade | Wolfe Research | Outperform → Peer Perform |
| Feb-10-23 | Upgrade | SVB Securities | Underperform → Market Perform |
| Nov-18-22 | Initiated | Credit Suisse | Outperform |
| Nov-08-22 | Downgrade | Societe Generale | Buy → Hold |
| Aug-01-22 | Downgrade | Atlantic Equities | Overweight → Neutral |
| May-23-22 | Initiated | SVB Leerink | Underperform |
| May-06-22 | Downgrade | Daiwa Securities | Outperform → Neutral |
| Apr-06-22 | Resumed | Morgan Stanley | Overweight |
| Feb-28-22 | Downgrade | UBS | Buy → Neutral |
| Feb-03-22 | Reiterated | BMO Capital Markets | Outperform |
| Feb-03-22 | Reiterated | Barclays | Equal Weight |
| Feb-03-22 | Reiterated | BofA Securities | Neutral |
| Feb-03-22 | Reiterated | Goldman | Neutral |
| Jan-13-22 | Initiated | Redburn | Buy |
| Jan-12-22 | Reiterated | BMO Capital Markets | Outperform |
| Dec-09-21 | Resumed | Wells Fargo | Overweight |
| Nov-23-21 | Upgrade | Societe Generale | Hold → Buy |
| Jul-27-21 | Resumed | Truist | Buy |
| Apr-07-21 | Resumed | RBC Capital Mkts | Outperform |
| Nov-10-20 | Resumed | Bernstein | Outperform |
| Sep-29-20 | Initiated | Berenberg | Hold |
| Jun-23-20 | Upgrade | Atlantic Equities | Neutral → Overweight |
| Jun-09-20 | Upgrade | Wolfe Research | Peer Perform → Outperform |
| Jun-02-20 | Upgrade | Argus | Hold → Buy |
| May-18-20 | Resumed | BofA/Merrill | Neutral |
| May-12-20 | Upgrade | JP Morgan | Neutral → Overweight |
| May-11-20 | Resumed | Morgan Stanley | Overweight |
| Apr-20-20 | Upgrade | RBC Capital Mkts | Sector Perform → Outperform |
| Mar-23-20 | Downgrade | Societe Generale | Buy → Hold |
| Feb-27-20 | Initiated | Barclays | Equal Weight |
| Feb-06-20 | Initiated | Mizuho | Buy |
| Jan-07-20 | Initiated | RBC Capital Mkts | Sector Perform |
| Dec-26-19 | Reiterated | Cowen | Outperform |
| Sep-26-19 | Upgrade | Citigroup | Neutral → Buy |
| Aug-20-19 | Upgrade | Piper Jaffray | Neutral → Overweight |
| Jun-27-19 | Upgrade | Wolfe Research | Underperform → Peer Perform |
| Jun-26-19 | Upgrade | SVB Leerink | Mkt Perform → Outperform |
| May-28-19 | Initiated | Goldman | Neutral |
| Apr-29-19 | Upgrade | BMO Capital Markets | Underperform → Market Perform |
View All
Abbvie Inc Stock (ABBV) Latest News
Should I hold or sell AbbVie Inc. stock in 20252025 Bull vs Bear & Accurate Intraday Trading Signals - DonanımHaber
Czech National Bank Grows Position in AbbVie Inc. $ABBV - MarketBeat
Is AbbVie Inc. stock supported by free cash flowPortfolio Value Summary & Free Real-Time Market Sentiment Alerts - DonanımHaber
Why analysts raise outlook for AbbVie Inc. (Common Stock) (4AB0) stock2025 Performance Recap & Community Driven Trade Alerts - Улправда
Is AbbVie Inc. stock a top pick in earnings seasonJuly 2025 Breakouts & AI Driven Price Forecasts - Улправда
AbbVie Stock (ABBV) After Hours Today: What’s Moving the Shares on Dec. 18, 2025 — and What to Watch Before the Market Opens Friday - ts2.tech
Will AbbVie Inc. stock see insider buying2025 Market Overview & Verified Chart Pattern Signals - Улправда
Is AbbVie a Millionaire Maker? - AOL.com
How cyclical is AbbVie Inc. stock compared to rivals2025 Trade Ideas & Risk Adjusted Buy/Sell Alerts - Улправда
August 2026 Options Now Available For AbbVie (ABBV) - Nasdaq
White House Readies Drug Price Deals With AbbVie, Novartis, Roche - Benzinga
AbbVie Inc. (ABBV) Starts Building $70 Million Expansion of Its AbbVie Bioresearch Centre in Worcester, Massachusetts - MSN
34,329 Shares in AbbVie Inc. $ABBV Purchased by Montecito Bank & Trust - MarketBeat
Thurston Springer Miller Herd & Titak Inc. Cuts Stake in AbbVie Inc. $ABBV - MarketBeat
Union Bancaire Privee UBP SA Boosts Stake in AbbVie Inc. $ABBV - MarketBeat
IPO Launch: Is AbbVie Inc. stock a top pick in earnings seasonJuly 2025 EndofMonth & Daily Stock Trend Reports - Улправда
AbbVie Inc. $ABBV Shares Sold by Carolina Wealth Advisors LLC - MarketBeat
Assenagon Asset Management S.A. Sells 1,106,627 Shares of AbbVie Inc. $ABBV - MarketBeat
University of Chicago Extends Collaboration with AbbVie to Advance Clinical Research and Patient Outcomes in Oncology | Newswise - Newswise
Analysts split on AbbVie Inc. (ABBV) as BofA cuts target and HSBC turns bullish - MSN
AbbVie, several other pharma companies near MFN deal with Trump, sources say - Reuters
Analysts Split on AbbVie Inc. (ABBV) as BofA Cuts Target and HSBC Turns Bullish - Insider Monkey
Looking At AbbVie's Recent Unusual Options Activity - Benzinga
Final trades: AbbVie Inc, Microsoft, Netflix and Twilio Inc - MSN
Want Decades of Passive Income? Buy This ETF and Hold It Forever. - The Motley Fool
Final Trades: Abbvie Inc, Microsoft, Netflix and Twilio Inc - CNBC
Evercore ISI Adjusts AbbVie Price Target to $233 From $222, Maintains Outperform Rating - marketscreener.com
TruWealth Advisors LLC Boosts Stock Position in AbbVie Inc. $ABBV - MarketBeat
Is Trending Stock AbbVie Inc. (ABBV) a Buy Now? - Yahoo Finance
Sanders Morris Harris LLC Grows Stock Position in AbbVie Inc. $ABBV - MarketBeat
Gradient Investments LLC Reduces Stake in AbbVie Inc. $ABBV - MarketBeat
Aaron Wealth Advisors LLC Increases Stock Position in AbbVie Inc. $ABBV - MarketBeat
Has AbbVie’s 24.6% 2025 Rally Left Further Upside After Strong DCF Signals? - Yahoo Finance
AbbVie Stock (ABBV) News, Forecasts and Analysis for Dec. 16, 2025: BofA Trims Target as Pipeline Catalysts Stay in Focus - ts2.tech
AbbVie (NYSE:ABBV) Stock Price Down 1.6%Here's What Happened - MarketBeat
AbbVie Inc. Stock Outperforms Competitors Despite Losses On The Day - 富途牛牛
How AbbVie's pipeline is lining up key product launches - MSN
How AbbVie's Pipeline Is Lining Up Key Product Launches - The Globe and Mail
AbbVie price target lowered to $233 from $248 at BofA - Yahoo Finance
St. Louis Financial Planners Asset Management LLC Takes $3.39 Million Position in AbbVie Inc. $ABBV - MarketBeat
32,205 Shares in AbbVie Inc. $ABBV Purchased by Shorepoint Capital Partners LLC - MarketBeat
Park National Corp OH Decreases Stock Holdings in AbbVie Inc. $ABBV - MarketBeat
Corient Private Wealth LLC Boosts Stock Position in AbbVie Inc. $ABBV - MarketBeat
AbbVie Inc. $ABBV Shares Purchased by GAMMA Investing LLC - MarketBeat
Is AbbVie stock too cheap to ignore at today's price? - MSN
AbbVie (NYSE:ABBV) Stock Price Up 1.9%Time to Buy? - MarketBeat
AbbVie (ABBV) Gains As Market Dips: What You Should Know - Yahoo Finance
AbbVie’s Growth Story Faces A Pipeline Pause - Finimize
AbbVie (ABBV) Stock in December 2025: Atogepant Breakthrough, Q3 Beat and 2026 Outlook After Medicare Price Cuts - ts2.tech
AbbVie Inc. stock outperforms competitors on strong trading day - MarketWatch
AbbVie (ABBV) Stock News and Forecasts Today: BofA Cuts Price Target to $233 as Wall Street Debates 2026 Pipeline Catalysts - ts2.tech
Abbvie Inc Stock (ABBV) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.96%
0.18%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):